ScholarIQanswers from OpenAlex & ORCID
Odd Erik Johansen
ResearcherPublications, citations & collaboration network
Odd Erik Johansen is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Odd Erik Johansen have?
ScholarIQindexed works
Odd Erik Johansen has 225 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Odd Erik Johansen have?
ScholarIQcitation count
Odd Erik Johansen has 26,812 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Odd Erik Johansen?
ScholarIQh-index
Odd Erik Johansen has an h-index of 40 in OpenAlex.
What is the i10-index of Odd Erik Johansen?
ScholarIQi10-index
Odd Erik Johansen has an i10-index of 87 in OpenAlex.
What is the ORCID of Odd Erik Johansen?
ScholarIQorcid
The ORCID for Odd Erik Johansen is on the source record.
What is the OpenAlex record for Odd Erik Johansen?
ScholarIQopenalex
The OpenAlex for Odd Erik Johansen is on the source record.
What are the most-cited papers on Odd Erik Johansen?
ScholarIQmost cited works
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, Silvio E. Inzucchi
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner, Silvio E. Inzucchi, John M. Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, Bernard Zinman
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z.I. Cherney, Bruce A. Perkins, Nima Soleymanlou, M Maione, Vesta Lai, Alana Lee, Nora Fagan, Hans J. Woerle, Odd Erik Johansen, Uli C. Broedl, Maximilian von Eynatten
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen, Mark E. Cooper, Steven E. Kahn, Nikolaus Marx, John H. Alexander, Michael Pencina, Robert D. Toto, Christoph Wanner, Bernard Zinman, Hans J. Woerle, David Baanstra, Egon Pfarr, Sven Schnaidt, Thomas Meinicke, Jyothis T. George, Maximilian von Eynatten, Darren K. McGuire, for the CARMELINA Investigators
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME <sup>®</sup> trial
David Fitchett, Bernard Zinman, Christoph Wanner, John M. Lachin, Stefan Hantel, Afshin Salsali, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, Silvio E. Inzucchi